In vivo positron emission tomography imaging with [11C]ABP688: Binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 6, 2011, Pages 1083-1094

  Delorenzo, Christine ^a   Milak, Matthew S ^a,b   Brennan, Kathleen G ^a   Kumar, J S Dileep ^a,b   Mann, J John ^a,b   Parsey, Ramin V ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

11C ABP688; Glutamate; Metabotropic glutamate receptor subtype 5; MTEP; Occupancy; Positron emission tomography

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; [3 (6 METHYLPYRIDIN 2 YLETHYNYL)CYCLOHEX 2 ENONE O METHYLOXIME] C 11; ABP 688; GLUTAMATE RECEPTOR 5; OXIME DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BABOON; COMPARTMENT MODEL; DRUG RECEPTOR BINDING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RECEPTOR AFFINITY; TEST RETEST RELIABILITY;

ANIMALS; BIOLOGICAL TRANSPORT; CARBON RADIOISOTOPES; MALE; OXIMES; PAPIO; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRIDINES; RECEPTORS, METABOTROPIC GLUTAMATE; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY;

EID: 79958023687     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-010-1723-7     Document Type: Article

References (61)

1. Siegel GJ. Basic neurochemistry: molecular, cellular, and medical aspects. 7th ed. Amsterdam: Elsevier; 2006.
2. A Palucha A Pilc 2007 Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs Pharmacol Ther 115 116 147 10.1016/j.pharmthera.2007.04.007 17582504 10.1016/j.pharmthera.2007.04.007 1:CAS:528:DC%2BD2sXntFyitbs%3D (Pubitemid 46992810)
3. CM Niswender PJ Conn 2010 Metabotropic glutamate receptors: physiology, pharmacology, and disease Annu Rev Pharmacol Toxicol 50 295 322 10.1146/annurev.pharmtox.011008.145533 20055706 10.1146/annurev.pharmtox.011008. 145533 1:CAS:528:DC%2BC3cXisVelurg%3D
4. W Spooren T Ballard F Gasparini M Amalric V Mutel R Schreiber 2003 Insight into the function of group I and group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders Behav Pharmacol 14 257 277 10.1097/01.fbp. 0000081783.35927.8f 12838033 10.1097/01.fbp.0000081783.35927.8f 1:CAS:528:DC%2BD3sXltFKjsbg%3D (Pubitemid 36900596)
5. CW Lindsley WD Shipe SE Wolkenberg CR Theberge DL Williams Jr C Sur, et al. 2006 Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia Curr Top Med Chem 6 771 785 16719816 10.2174/156802606777057599 1:CAS:528:DC%2BD28XmtVahsLw%3D
6. F Liu S Grauer C Kelley R Navarra R Graf G Zhang, et al. 2008 ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl] -piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities J Pharmacol Exp Ther 327 827 839 10.1124/jpet.108.136580 18753411 10.1124/jpet.108.136580 1:CAS:528:DC%2BD1cXhsVCjtLjN
7. MJ Marino PJ Conn 2002 Direct and indirect modulation of the N-methyl D-aspartate receptor Curr Drug Targets CNS Neurol Disord 1 1 16 12769631 10.2174/1568007023339544 1:CAS:528:DC%2BD38Xit1Ggtbw%3D
8. JT Gass MP Osborne NL Watson JL Brown MF Olive 2009 MGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats Neuropsychopharmacology 34 820 833 10.1038/npp.2008.140 18800068 10.1038/npp.2008.140 1:CAS:528: DC%2BD1MXhs1antrs%3D
9. A Markou 2009 Accruing preclinical evidence about metabotropic glutamate 5 receptor antagonists as treatments for drug dependence highlights the irreplaceable contributions of animal studies to the discovery of new medications for human disorders Neuropsychopharmacology 34 817 819 10.1038/Npp. 2008.218 19092781 10.1038/npp.2008.218 1:CAS:528:DC%2BD1MXhs1ansb8%3D
10. JA Aguirre J Kehr T Yoshitake FL Liu A Rivera S Fernandez-Espinola, et al. 2005 Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP Brain Res 1033 216 220 10.1016/j.brainres.2004.11.040 15694927 10.1016/j.brainres.2004.11.040 1:CAS:528:DC%2BD2MXhtVOru7w%3D (Pubitemid 40193417)
11. MR Domenici RL Potenza A Martire R Coccurello A Pezzola R Reggio, et al. 2005 Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease J Neurosci Res 80 646 654 10.1002/jnr.20489 15880742 10.1002/jnr.20489 1:CAS:528:DC%2BD2MXltFagtb0%3D (Pubitemid 40896185)
12. N Turle-Lorenzo N Breysse C Baunez M Amalric 2005 Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease Psychopharmacology (Berl) 179 117 127 10.1007/s00213-005-2202-x 10.1007/s00213-005-2202-x 1:CAS:528:DC%2BD2MXjtV2itbk%3D (Pubitemid 40576698)
13. J Elia X Gai HM Xie JC Perin E Geiger JT Glessner, et al. 2009 Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes Mol Psychiatry 15 637 646 10.1038/mp.2009.57 19546859 10.1038/mp.2009.57
14. E Aronica JA Gorter GH Jansen CW van Veelen PC van Rijen M Ramkema, et al. 2003 Expression and cell distribution of group I and group II metabotropic glutamate receptor subtypes in taylor-type focal cortical dysplasia Epilepsia 44 785 795 12790891 10.1046/j.1528-1157.2003.54802.x 1:CAS:528: DC%2BD3sXlvFWktrk%3D (Pubitemid 36754003)
15. G Dolen MF Bear 2008 Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome J Physiol 586 1503 1508 10.1113/jphysiol.2008.150722 18202092 10.1113/jphysiol.2008.150722 1:CAS:528:DC%2BD1cXktVeku7o%3D (Pubitemid 351404955)
16. K Kanuma T Aoki Y Shimazaki 2010 Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia Recent Pat CNS Drug Discov 5 23 34 19832691 10.2174/ 157488910789753512 1:CAS:528:DC%2BC3cXisVKls74%3D
17. MR Stefani B Moghaddam 2010 Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade Eur J Pharmacol. 639 26 32 10.1016/j.ejphar.2010.01.028 20371234 10.1016/j.ejphar.2010.01.028 1:CAS:528:DC%2BC3cXntVShu7o%3D
18. G Dolen RL Carpenter TD Ocain MF Bear 2010 Mechanism-based approaches to treating fragile X Pharmacol Ther 127 78 93 10.1016/j.pharmthera.2010.02.008 20303363 10.1016/j.pharmthera.2010.02.008
19. L Steru R Chermat B Thierry P Simon 1985 The tail suspension test: a new method for screening antidepressants in mice Psychopharmacology (Berl) 85 367 370 10.1007/BF00428203 1:CAS:528:DyaL2MXksVOkt7k%3D (Pubitemid 15123115)
20. RD Porsolt G Anton N Blavet M Jalfre 1978 Behavioural despair in rats: a new model sensitive to antidepressant treatments Eur J Pharmacol 47 379 391 204499 10.1016/0014-2999(78)90118-8 1:CAS:528:DyaE1cXhvVagsr0%3D
21. IV Belozertseva T Kos P Popik W Danysz AY Bespalov 2007 Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests Eur Neuropsychopharmacol 17 172 179 16630709 10.1016/j.euroneuro.2006.03.002 1:CAS:528:DC%2BD28Xht1eqsLrF (Pubitemid 44779190)
22. A Palucha P Branski B Szewczyk JM Wieronska K Klak A Pilc 2005 Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist Pharmacol Biochem Behav 81 901 906 16040106 10.1016/j.pbb.2005.06.015 1:CAS:528:DC%2BD2MXos1Wrurw%3D (Pubitemid 41187826)
23. X Li AB Need M Baez JM Witkin 2006 Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice J Pharmacol Exp Ther 319 254 259 10.1124/jpet.106.103143 16803860 10.1124/jpet.106.103143 1:CAS:528:DC%2BD28XhtVCksL3L (Pubitemid 44455130)
24. A Pilc A Klodzinska P Branski G Nowak A Palucha B Szewczyk, et al. 2002 Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats Neuropharmacology 43 181 187 12213272 10.1016/S0028-3908(02)00082-5 1:CAS:528:DC%2BD38Xms1Gqtbk%3D (Pubitemid 35247606)
25. JM Wieronska B Szewczyk P Branski A Palucha A Pilc 2002 Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats Amino Acids 23 213 216 10.1007/s00726-001-0131-5 12373540 10.1007/s00726-001-0131-5 1:CAS:528:DC%2BD38Xns1Gnsb0%3D
26. S Hintermann I Vranesic H Allgeier A Brulisauer D Hoyer M Lemaire, et al. 2007 ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies Bioorg Med Chem 15 903 914 17110115 10.1016/j.bmc.2006. 10.038 1:CAS:528:DC%2BD28XhtleisL3J (Pubitemid 44880714)
27. RH Porter G Jaeschke W Spooren TM Ballard B Buttelmann S Kolczewski, et al. 2005 Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity J Pharmacol Exp Ther 315 711 721 16040814 10.1124/jpet.105. 089839 1:CAS:528:DC%2BD2MXhtFyhtr7F (Pubitemid 41500737)
28. JC Pecknold DJ McClure L Appeltauer L Wrzesinski T Allan 1982 Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study J Clin Psychopharmacol 2 129 133 7042771 10.1097/00004714-198204000-00010 1:STN:280:DyaL387ptVCqtA%3D%3D (Pubitemid 12025672)
29. SM Ametamey LJ Kessler M Honer MT Wyss A Buck S Hintermann, et al. 2006 Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5 J Nucl Med 47 698 705 16595505 1:CAS:528:DC%2BD28Xkt1Oisr8%3D (Pubitemid 46768472)
30. F Gasparini H Andres PJ Flor M Heinrich W Inderbitzin K Lingenhohl, et al. 2002 [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5 Bioorg Med Chem Lett 12 407 409 11814808 10.1016/S0960-894X(01)00767-3 1:CAS:528:DC%2BD38XpslKrtg%3D%3D (Pubitemid 34113914)
31. D Elmenhorst L Minuzzi A Aliaga J Rowley G Massarweh M Diksic, et al. 2010 In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688 J Cereb Blood Flow Metab 30 1538 1539 10.1038/jcbfm.2010. 65 20531460 10.1038/jcbfm.2010.65 1:CAS:528:DC%2BC3cXpsFeks7c%3D
32. MT Wyss SM Ametamey V Treyer A Bettio M Blagoev LJ Kessler, et al. 2007 Quantitative evaluation of 11C-ABP688 as PET ligand for the measurement of the metabotropic glutamate receptor subtype 5 using autoradiographic studies and a beta-scintillator Neuroimage. 35 1086 1092 10.1016/j.neuroimage.2007.01.005 17320417 10.1016/j.neuroimage.2007.01.005 (Pubitemid 46509846)
33. SM Ametamey V Treyer J Streffer MT Wyss M Schmidt M Blagoev, et al. 2007 Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688 J Nucl Med 48 247 252 17268022 1:CAS:528:DC%2BD2sXjsVKmsb0%3D (Pubitemid 47555351)
34. V Treyer J Streffer MT Wyss A Bettio SM Ametamey U Fischer, et al. 2007 Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods J Nucl Med 48 1207 1215 10.2967/jnumed.107. 039578 17574984 10.2967/jnumed.107.039578 1:CAS:528:DC%2BD2sXhtVertL%2FI (Pubitemid 47052662)
35. MP Johnson ES Nisenbaum TH Large R Emkey M Baez AE Kingston 2004 Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists Biochem Soc Trans 32 881 887 10.1042/BST0320881 15494040 10.1042/BST0320881 1:CAS:528:DC%2BD2cXptVSltro%3D (Pubitemid 39524404)
36. A Ritzen JM Mathiesen C Thomsen 2005 Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators Basic Clin Pharmacol Toxicol 97 202 213 10.1111/j.1742-7843.2005.pto-156.x 16176554 10.1111/j.1742-7843.2005.pto-156.x 1:CAS:528:DC%2BD2MXhtFantLfF (Pubitemid 41435091)
37. VJ Cunningham EA Rabiner M Slifstein M Laruelle RN Gunn 2010 Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited J Cereb Blood Flow Metab 30 46 50 10.1038/jcbfm.2009.190 19738632 10.1038/jcbfm.2009.190
38. MS Milak RT Ogden DN Vinocur RL Van Heertum TB Cooper JJ Mann, et al. 2005 Effects of tryptophan depletion on the binding of [11C]-DASB to the serotonin transporter in baboons: response to acute serotonin deficiency Biol Psychiatry. 57 102 106 10.1016/j.biopsych.2004.09.026 15607307 10.1016/j.biopsych.2004.09.026 1:CAS:528:DC%2BD2cXhtVyqsrbJ (Pubitemid 39647598)
39. CS Busse J Brodkin D Tattersall JJ Anderson N Warren L Tehrani, et al. 2004 The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1, 3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety Neuropsychopharmacology 29 1971 1979 15305166 10.1038/sj.npp.1300540 1:CAS:528:DC%2BD2cXoslSkurc%3D (Pubitemid 39486548)
40. JJ Anderson MJ Bradbury DR Giracello DF Chapman G Holtz J Roppe, et al. 2003 In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine) Eur J Pharmacol 473 35 40 12877935 10.1016/S0014-2999(03)01935-6 1:CAS:528:DC%2BD3sXls1Omu74%3D (Pubitemid 36851626)
41. K Stachowicz K Golembiowska M Sowa G Nowak E Chojnacka-Wojcik A Pilc 2007 Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent Neuropharmacology 53 741 748 10.1016/j.neuropharm. 2007.08.002 17870136 10.1016/j.neuropharm.2007.08.002 1:CAS:528: DC%2BD2sXhtFGrsL3O (Pubitemid 47532144)
42. C DeLorenzo JSD Kumar F Zanderigo JJ Mann RV Parsey 2009 Modeling considerations for in vivo quantification of the dopamine transporter using [C-11]PE2I and positron emission tomography J Cereb Blood Flow Metab 29 1332 1345 10.1038/Jcbfm.2009.49 19458606 10.1038/jcbfm.2009.49 1:CAS:528: DC%2BD1MXnvVyit7o%3D
43. RT Ogden A Ojha K Erlandsson MA Oquendo JJ Mann RV Parsey 2007 In vivo quantification of serotonin transporters using [(11)C]DASB and positron emission tomography in humans: modeling considerations J Cereb Blood Flow Metab 27 205 217 10.1038/sj.jcbfm.9600329 16736050 10.1038/sj.jcbfm.9600329 1:CAS:528:DC%2BD2sXptleqsA%3D%3D (Pubitemid 46006598)
44. Kwon Y. Handbook of essential pharmacokinetics, pharmacodynamics, and drug metabolism for industrial scientists. New York: Kluwer Academic/Plenum Publishers; 2001.
45. JJHM Lohman 1986 Plasma-protein binding of drugs - implications for therapeutic drug-monitoring Pharm Weekbl Sci Ed 8 302 304 1:CAS:528: DyaL2sXhsVyrs7s%3D
46. RN Gunn PA Sargent CJ Bench EA Rabiner S Osman VW Pike, et al. 1998 Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET Neuroimage 8 426 440 10.1006/nimg.1998.0379 9811559 10.1006/nimg.1998. 0379 1:STN:280:DyaK1M%2FjtVOmsg%3D%3D (Pubitemid 28545940)
47. RB Innis VJ Cunningham J Delforge M Fujita A Gjedde RN Gunn, et al. 2007 Consensus nomenclature for in vivo imaging of reversibly binding radioligands J Cereb Blood Flow Metab. 27 1533 1539 10.1038/sj.jcbfm.9600493 17519979 10.1038/sj.jcbfm.9600493 1:CAS:528:DC%2BD2sXptlSqtrc%3D (Pubitemid 47301451)
48. RV Parsey M Slifstein DR Hwang A Abi-Dargham N Simpson O Mawlawi, et al. 2000 Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tissue input functions J Cereb Blood Flow Metab 20 1111 1133 10.1097/00004647-200007000-00011 10908045 10.1097/00004647-200007000-00011 1:CAS:528:DC%2BD3cXltFOmu74%3D (Pubitemid 30445623)
49. J Logan JS Fowler ND Volkow AP Wolf SL Dewey DJ Schlyer, et al. 1990 Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects J Cereb Blood Flow Metab 10 740 747 2384545 10.1038/jcbfm.1990.127 1:CAS:528:DyaK3cXmtVOmu7Y%3D (Pubitemid 20260955)
50. M Slifstein M Laruelle 2000 Effects of statistical noise on graphic analysis of PET neuroreceptor studies J Nucl Med 41 2083 2088 11138696 1:STN:280:DC%2BD3M%2FoslSltw%3D%3D (Pubitemid 32038700)
51. RT Ogden 2003 Estimation of kinetic parameters in graphical analysis of PET imaging data Stat Med 22 3557 3568 10.1002/sim.1562 14601019 10.1002/sim.1562 (Pubitemid 37407350)
52. AA Lammertsma SP Hume 1996 Simplified reference tissue model for PET receptor studies Neuroimage 4 153 158 9345505 10.1006/nimg.1996.0066 1:STN:280:DyaK1c%2FgsFeltw%3D%3D (Pubitemid 27024284)
53. J Logan JS Fowler ND Volkow GJ Wang YS Ding DL Alexoff 1996 Distribution volume ratios without blood sampling from graphical analysis of PET data J Cereb Blood Flow Metab 16 834 840 8784228 10.1097/00004647-199609000-00008 1:STN:280:DyaK28znvVKltw%3D%3D (Pubitemid 26292051)
54. RT Ogden T Tarpey 2006 Estimation in regression models with externally estimated parameters Biostatistics 7 115 129 10.1093/biostatistics/kxi044 16020616 10.1093/biostatistics/kxi044 (Pubitemid 43007185)
55. BA Ardekani S Guckemus A Bachman MJ Hoptman M Wojtaszek J Nierenberg 2005 Quantitative comparison of algorithms for inter-subject registration of 3D volumetric brain MRI scans J Neurosci Methods 142 67 76 10.1016/j.jneumeth.2004. 07.014 15652618 10.1016/j.jneumeth.2004.07.014 (Pubitemid 40138029)
56. NA Lassen PA Bartenstein AA Lammertsma MC Prevett DR Turton SK Luthra, et al. 1995 Benzodiazepine receptor quantification in-vivo in humans using [C-11] flumazenil and PET - application of the steady-state principle J Cereb Blood Flow Metab. 15 152 165 7798333 10.1038/jcbfm.1995.17 1:CAS:528: DyaK2MXjsVWlsro%3D
57. ND Cosford L Tehrani J Roppe E Schweiger ND Smith J Anderson, et al. 2003 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity J Med Chem 46 204 206 10.1021/jm025570j 12519057 10.1021/jm025570j 1:CAS:528:DC%2BD38XpsVensLk%3D (Pubitemid 36078139)
58. JM Mathiesen N Svendsen H Brauner-Osborne C Thomsen MT Ramirez 2003 Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP Br J Pharmacol 138 1026 1030 10.1038/sj.bjp. 0705159 12684257 10.1038/sj.bjp.0705159 1:CAS:528:DC%2BD3sXjtVahsLc%3D (Pubitemid 36459824)
59. ND Cosford J Roppe L Tehrani EJ Schweiger TJ Seiders A Chaudary, et al. 2003 [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor Bioorg Med Chem Lett 13 351 354 12565928 10.1016/S0960-894X(02)00997-6 1:CAS:528:DC%2BD3sXptFalsQ%3D%3D (Pubitemid 36259690)
60. M Honer A Stoffel LJ Kessler PA Schubiger SM Ametamey 2007 Radiolabeling and in vitro and in vivo evaluation of [(18)F]-FE-DABP688 as a PET radioligand for the metabotropic glutamate receptor subtype 5 Nucl Med Biol 34 973 980 17998101 10.1016/j.nucmedbio.2007.07.017 1:CAS:528:DC%2BD2sXht12jtrrK (Pubitemid 350081076)
61. S Patel TG Hamill B Connolly E Jagoda W Li RE Gibson 2007 Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18 F]F-PEB Nucl Med Biol 34 1009 1017 10.1016/j.nucmedbio.2007.07.009 17998106 10.1016/j.nucmedbio.2007.07.009 1:CAS:528:DC%2BD2sXht12jtr%2FP (Pubitemid 350061172)